These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20118638)

  • 1. [Viral safety of biologicals: evaluation of hepatitis C virus (HCV) nucleic acid amplification test (NAT) assay and development of concentration method of HCV for sensitive detection by NAT].
    Uchida E; Yamaguchi T
    Yakugaku Zasshi; 2010 Feb; 130(2):163-9. PubMed ID: 20118638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays.
    Kretzschmar E; Chudy M; Nübling CM; Ross RS; Kruse F; Trobisch H
    Vox Sang; 2007 May; 92(4):297-301. PubMed ID: 17456153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.
    Assal A; Barlet V; Deschaseaux M; Dupont I; Gallian P; Guitton C; Morel P; van Drimmelen H; David B; Lelie N; De Micco P
    Transfusion; 2009 Feb; 49(2):301-10. PubMed ID: 19389212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the nucleic acid amplification test (NAT) be an alternative to the serologic tests? A prospective study, the results of 18,200 blood donors from the Turkish Red Crescent.
    Kosan E; Kocazeybek B; Altunay H; Aymelek M; Alan E; Saribas S; Aslan M; Yenen OS; Yuksel P; Birinci I; Kirali K; Aksoy A
    Transfus Apher Sci; 2010 Dec; 43(3):269-272. PubMed ID: 20943441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation.
    Watson J; Mulvihill MS; Cox ML; Rich L; Wolfe CR; Gray A; Hartwig MG
    Clin Transplant; 2019 Mar; 33(3):e13476. PubMed ID: 30609162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in the Netherlands utilizing nucleic acid amplification technology for blood screening.
    Cuijpers HT; Molijn MH; Bos HJ; Peeters AP; van der Poel CL; Lelie PN
    Vox Sang; 2001 Jul; 81(1):12-20. PubMed ID: 11520410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.
    Makroo RN; Choudhury N; Jagannathan L; Parihar-Malhotra M; Raina V; Chaudhary RK; Marwaha N; Bhatia NK; Ganguly AK
    Indian J Med Res; 2008 Feb; 127(2):140-7. PubMed ID: 18403791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deceased organ donor screening for human immunodeficiency virus, hepatitis B virus and hepatitis C virus: Discordant serology and nucleic acid testing results.
    Theodoropoulos N; Nowicki MJ; Chinchilla-Reyes C; Dionne S; Jaramillo A; Mone T; Hasz R; Jendrisak MD; Ladner DP; Ison MG
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
    Katsoulidou A; Moschidis Z; Sypsa V; Chini M; Papatheodoridis GV; Tassopoulos NC; Mimidis K; Karafoulidou A; Hatzakis A
    Vox Sang; 2007 Jan; 92(1):8-14. PubMed ID: 17181585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?
    Laperche S; Elghouzzi MH; Morel P; Asso-Bonnet M; Le Marrec N; Girault A; Servant-Delmas A; Bouchardeau F; Deschaseaux M; Piquet Y
    Transfusion; 2005 Dec; 45(12):1965-72. PubMed ID: 16371051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.
    Busch MP; Glynn SA; Wright DJ; Hirschkorn D; Laycock ME; McAuley J; Tu Y; Giachetti C; Gallarda J; Heitman J; Kleinman SH;
    Transfusion; 2005 Dec; 45(12):1853-63. PubMed ID: 16371038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide nucleic acid amplification testing of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow-up study of nucleic acid amplification positive donors.
    Japanese Red Cross NAT Screening Research Group
    Jpn J Infect Dis; 2000 Jun; 53(3):116-23. PubMed ID: 10957709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of triplex nucleic acid test assays in United States blood donors.
    Stramer SL; Krysztof DE; Brodsky JP; Fickett TA; Reynolds B; Dodd RY; Kleinman SH
    Transfusion; 2013 Oct; 53(10 Pt 2):2525-37. PubMed ID: 23550838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.